Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07014488 | A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects | completed | Phase 1 | 16 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06689163 |
| A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone |
| recruiting |
| Phase 1 / Phase 2 |
| 66 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 1 |
| Sep 3, 2025 |
| clinicaltrials |
| NCT06703437 | Long Acting Neuraxial Peri-prostatic Block in Cancer | active not recruiting | Phase 1 | 12 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07149831 | A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults | recruiting | Phase 1 | 6 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT04666129 | Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 48 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | terminated | Phase 1 | 96 | Lava TherapeuticsINDUSTRY | 3 | Aug 1, 2025 | clinicaltrials |
| NCT05544227 | Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 15 | Williams Cancer FoundationOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | terminated | Phase 1 / Phase 2 | 23 | University of OxfordOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | terminated | Phase 1 | 42 | AmgenINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06389695 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | completed | Phase 1 / Phase 2 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | terminated | Phase 1 | 2 | Rahul AggarwalOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT00328614 | Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer | completed | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01420250 | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer(LuPARP) | active not recruiting | Phase 1 | 70 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03300505 | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 9 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06139575 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 90 | Bivision Pharmaceuticals, Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04186585 | Recommended Dose Estimation of BP-C2 | recruiting | Phase 1 | 8 | MeddocOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | terminated | Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02603965 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02339168 | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 | 25 | University of California, DavisOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 19 | Opna Bio LLCINDUSTRY | 2 | Apr 8, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06377683 | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 8 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite LavalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | terminated | Phase 1 / Phase 2 | 75 | BioNTech SEINDUSTRY | 4 | Mar 20, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Sep 10, 2025source: clinicaltrials